Price
$42.30+23.50%Social Signal Score
Analyst Ratings
30 analystsRevenue
$547.87M+49.48%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jon Pratt
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 5,400
- Beta
- 0.56
- Country
- NL
- Piotroski score
- 9 / 9 (Strong)
- Altman Z-score
- 4.01
Financials
Revenue
$547.87M+49.5%Net Income
$105.66M+882.1%EBITDA
$195.88M+251.0%Free Cash Flow
$105.59M+43.4%EPS (diluted)
$0.51+1235.1%Shares Outstanding (diluted)
208.06M-9.8%Operating Expenses
$200.07MCash & Debt
$830.13MReturn of Capital
$0.00Revenue by Segment (annual)
$4.18BDividend per Share
$0.35Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.09B | $424.88M | $2.04 |
| 2024 | $1.98B | $83.59M | $0.39 |
| 2023 | $1.97B | $341.30M | $1.67 |
| 2022 | $2.14B | $423.21M | $2.08 |
| 2021 | $2.25B | $512.60M | $2.52 |
| 2020 | $1.87B | $359.19M | $0.33 |
| 2019 | $1.53B | $-41.45M | $-0.19 |
| 2018 | $1.50B | $190.38M | $0.84 |
| 2017 | $1.42B | $40.39M | $0.18 |
| 2016 | $1.34B | $80.40M | $0.36 |
| 2015 | $1.28B | $130.15M | $0.57 |
| 2014 | $1.34B | $116.36M | $0.52 |
| 2013 | $1.30B | $69.07M | $0.31 |
| 2012 | $1.25B | $129.51M | $0.57 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from QGEN's reported EPS growth of 10.3% a year over 13 years.
- EPS in 5 years
- $3.34
- Implied price
- $76.73
- Return from $49.30
- 9.2% a year
To earn 15.0% a year on these assumptions you'd need to buy at $38.15 — -22.6% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 17 | 20 | 23 | 26 | 29 |
|---|---|---|---|---|---|
| 0.3% | -6.5% | -3.4% | -0.7% | 1.8% | 4.1% |
| 5.3% | -1.8% | 1.4% | 4.3% | 6.9% | 9.2% |
| 10.3% | 2.8% | 6.2% | 9.2% | 12.0% | 14.4% |
| 15.3% | 7.5% | 11.1% | 14.2% | 17.0% | 19.6% |
| 20.3% | 12.2% | 15.9% | 19.2% | 22.1% | 24.8% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
80-38.46%Social Signal Score
Mentions (15)
- Newszacks.com·9d ago·Negative
Interpreting Qiagen (QGEN) International Revenue Trends Review Qiagen's (QGEN) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
View source ↗ - Newsseekingalpha.com·16d ago·Neutral
Qiagen N.V. (QGEN) Shareholder/Analyst Call Prepared Remarks Transcript Qiagen N.V. ( QGEN ) Shareholder/Analyst Call November 6, 2026 8:00 AM EST Company Participants Roland Sackers - CFO, MD & Member of Management Board Presentation Roland Sackers CFO, MD & Member of Management Board Good morning, good afternoon.
View source ↗ - Newszacks.com·18d ago·Negative
Compared to Estimates, Qiagen (QGEN) Q3 Earnings: A Look at Key Metrics Although the revenue and EPS for Qiagen (QGEN) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
View source ↗ - Newszacks.com·22d ago·Neutral
Do Options Traders Know Something About Qiagen Stock We Don't? Investors need to pay close attention to QGEN stock based on the movements in the options market lately.
View source ↗ - Newsbenzinga.com·31d ago·Negative
This Qiagen Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
View source ↗ - Newsbusinesswire.com·32d ago·Neutral
QIAGEN reports preliminary Q3 2026 results VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary third-quarter 2026 financial results. Net sales were $548 million at both reported and constant exchange rates (CER). Adjusted diluted earnings per share (EPS) were $0.65, also $0.65 CER. QIAGEN plans to report full Q3 2026 results on Wednesday, November 4, 2026, at approximately 22:05 Frankfurt time / 16:05 New York…
View source ↗ - Newszacks.com·51d ago·Negative
QIAGEN Expands US QIAstat-Dx Portfolio With New FDA-Cleared Panel QGEN expands its U.S. QIAstat-Dx portfolio with an FDA-cleared panel that detects gram-negative bacteria and resistance markers in about one hour.
View source ↗ - Newsbusinesswire.com·55d ago·Negative
…mpletes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that U.S. laboratories now have access to the complete QIAstat-Dx bloodstream infection portfolio following clearance of a new panel by the U.S. Food and Drug Administration (FDA). The new panel detects gram-negative bacteria and antibiotic resista…
View source ↗ - Newszacks.com·59d ago·Positive
Here's Why You Should Hold QIAGEN Stock in Your Portfolio for Now QGEN's test menu expansion and strategic partnerships support growth, but cautious spending and competition may weigh on near-term gains.
View source ↗ - Newsseekingalpha.com·67d ago·Positive
Qiagen N.V. (QGEN) Presents at 2026 Global Healthcare Conference Transcript Qiagen N.V. (QGEN) Presents at 2026 Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·69d ago·Positive
Qiagen N.V. (QGEN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Qiagen N.V. (QGEN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newszacks.com·79d ago·Neutral
Qiagen (QGEN) Up 5.1% Since Last Earnings Report: Can It Continue? Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newsprnewswire.com·86d ago·Positive
…ing human health, today announced that a jury in the U.S. District Court for the District of Delaware found that Parse Biosciences, now a subsidiary of Qiagen (NYSE: QGEN), willfully infringed three patents exclusively licensed to Scale Biosciences, part of 10x Genomics since 2025.
View source ↗ - Newsbusinesswire.com·90d ago·Positive
QIAGEN Appoints Jonathan M. Pratt as Chief Executive Officer VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Jonathan M. Pratt has been appointed Chief Executive Officer, effective September 1, 2026. He brings to QIAGEN more than 25 years of international leadership experience across life sciences, laboratory technologies and healthcare. Jon Pratt most recently served as President and CEO of Filtration Group, lea…
View source ↗ - Newsmarketbeat.com·106d ago·Neutral
Qiagen Q2 Earnings Call Highlights Qiagen NYSE: QGEN reported second-quarter 2026 results above its prior outlook, with net sales of $535 million, unchanged year over year on both a reported and constant-exchange-rate basis. The company had forecast an approximately 2% decline at constant exchange rates.
View source ↗
Earnings
Wed, Feb 3(in 2 months)
Consensus estimate $0.66 per share
Typical surprise +3.7% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 4$0.65 vs $0.63beat
- Wed, Aug 5$0.62 vs $0.60beat
- Wed, May 6$0.54 vs $0.54miss
- Wed, Feb 4$0.62 vs $0.61beat
- Tue, Nov 4$0.64 vs $0.61beat
- Tue, Aug 5$0.60 vs $0.60beat
Estimates and results for QGEN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
- Ro Khannahouse · CA17 · disclosed May 6, 2022 (23d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Mar 8, 2022 (22d later)Buy$1,001 - $15,000
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (460d later)Sell$1,001 - $15,000
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (474d later)Sell$1,001 - $15,000
- Peter Welchhouse · VT00 · disclosed Apr 3, 2020 (10d later)Sell$1,001 - $15,000
- Peter Welchhouse · VT00 · disclosed Mar 10, 2020 (12d later)Buy$1,001 - $15,000
- Alan Lowenthalhouse · CA47 · disclosed Nov 8, 2019 (31d later)Sell$1,001 - $15,000
- Alan Lowenthalhouse · CA47 · disclosed Nov 8, 2019 (31d later)Sell$15,001 - $50,000
- Alan Lowenthalhouse · CA47 · disclosed Nov 7, 2019 (30d later)Sell$50,001 - $100,000
- Alan Lowenthalhouse · CA47 · disclosed Sep 21, 2019 (8d later)Buy$1,001 - $15,000
- Alan Lowenthalhouse · CA47 · disclosed Sep 21, 2019 (8d later)Buy$1,001 - $15,000
- Alan Lowenthalhouse · CA47 · disclosed Sep 21, 2019 (9d later)Buy$15,001 - $50,000
- Alan Lowenthalhouse · CA47 · disclosed Sep 21, 2019 (9d later)Buy$1,001 - $15,000
- Alan Lowenthalhouse · CA47 · disclosed Sep 21, 2019 (8d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
